Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation

Here we have carried out a multiparameter analysis using a panel of 28 immunohistochemical markers to identify markers of transformation from benign and dysplastic naevus to primary melanoma in three separate cohorts totalling 279 lesions. We have identified a set of eight markers that distinguish naevi from melanoma. None of markers or parameters assessed differentiated benign from dysplastic naevi. Indeed, the naevi clustered tightly in terms of their immunostaining patterns whereas primary melanomas showed more diverse staining patterns. A small subset of histopathologically benign lesions had elevated levels of multiple markers associated with melanoma, suggesting that these represent naevi with an increased potential for transformation to melanoma.

[1]  C. Rosendahl,et al.  Dysplastic nevus: Fact and fiction. , 2015, Journal of the American Academy of Dermatology.

[2]  N. Bardeesy,et al.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. , 2015, Cancer cell.

[3]  M. Tavel,et al.  The mythical concept and untoward consequences of a diagnosis of dysplastic nevus: an overdue tribute to A. Bernard Ackerman, MD , 2015, Dermatology practical & conceptual.

[4]  Jon Emery,et al.  Risk Prediction Models for Melanoma: A Systematic Review , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[5]  S. Hamilton-Dutoit,et al.  E‐ to N‐cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression , 2013, The British journal of dermatology.

[6]  T. Shlomi,et al.  A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence , 2013, Nature.

[7]  Benjamin G. Bitler,et al.  Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. , 2013, Cell reports.

[8]  M. Tucker,et al.  Dysplastic Nevi and Melanoma , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[9]  A. Weeraratna,et al.  A Wnt-er Migration: The Confusing Role of β-Catenin in Melanoma Metastasis , 2013, Science Signaling.

[10]  Dean Y. Li,et al.  The Small GTPase ARF6 Stimulates β-Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis , 2013, Science Signaling.

[11]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[12]  H. Horlings,et al.  Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.

[13]  Rodney J Scott,et al.  P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation , 2011, BMC Cancer.

[14]  D. Whiteman,et al.  Estimating the Attributable Fraction for Cancer: A Meta-analysis of Nevi and Melanoma , 2010, Cancer Prevention Research.

[15]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[16]  G. Walker.  Cutaneous melanoma: how does ultraviolet light contribute to melanocyte transformation? , 2008, Future oncology.

[17]  G. Robertson,et al.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. , 2008, Cancer research.

[18]  R. Marais,et al.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.

[19]  N. Hayward,et al.  Cutaneous melanoma susceptibility and progression genes. , 2005, Cancer letters.

[20]  L. Akslen,et al.  Importance of P-Cadherin, β-Catenin, and Wnt5a/Frizzled for Progression of Melanocytic Tumors and Prognosis in Cutaneous Melanoma , 2005, Clinical Cancer Research.

[21]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[22]  N. Hayward,et al.  Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. , 2003, Journal of the National Cancer Institute.

[23]  W. Goggins,et al.  The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. , 2003, Archives of dermatology.

[24]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[25]  P. Pollock,et al.  CDKN2A/p16 is inactivated in most melanoma cell lines. , 1997, Cancer research.

[26]  W. Clark,et al.  Dysplastic nevus syndrome: A phenotypic association of sporadic cutaneous melanoma , 1980, Cancer.

[27]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[28]  Nicholas,et al.  CDKN 2 A / p 16 Is Inactivated in Most Melanoma Cell Lines ' , 2006 .

[29]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[30]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[31]  M. Greenacre.  Correspondence analysis in practice , 1993 .